Article Details
Retrieved on: 2024-06-07 22:43:35
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Dupilumab had an acceptable long-term safety profile with sustained efficacy in children aged 6 months to 5 years who had inadequately controlled ...
Article found on: www.dermatologyadvisor.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here